24 HR tofacitinib 11 MG Extended Release Oral Tablet

RxCUI: 1741046
RxNorm name: 24 HR tofacitinib 11 MG Extended Release Oral Tablet
Display name: Tofacitinib XR (Oral Pill)
Full name: 24 HR tofacitinib 11 MG Extended Release Oral Tablet
Term type: SCD
Status: Active
Strength: 11 mg
Dose form: 24 HR XR Tab
Route: Oral Pill
Updated: 2026-10-22 07:00:18

RxNorm Status History#

Status: Active
Source: RXNORM
Current: YES
Release start: 042016
Active start: 042016
Multiple ingredient: NO
Branded: NO

Ingredients And Strength#

Ingredient, Strength, Base table
Ingredient	Strength	Base	Basis of strength
tofacitinib citrate	11 MG / 1 EACH	tofacitinib	tofacitinib

Dose Form Concepts#

Dose form, RxCUI table
Dose form	RxCUI
Extended Release Oral Tablet	316945

Derived Ingredient Concepts#

Ingredient, RxCUI table
Ingredient	RxCUI
tofacitinib	1357536

Source Vocabulary Codes#

Code type, Values, Count table
Code type	Values	Count	Category
PRESCRIBABLE	Y	1	ATTRIBUTES
RXNAV_STR	24 HR tofacitinib 11 MG Extended Release Oral Tablet	1	NAMES
RxNorm Name	24 HR tofacitinib 11 MG Extended Release Oral Tablet	1	NAMES
RxNorm Synonym	2 linked values tofacitinib 11 MG (as tofacitinib citrate 17.77 MG) 24 HR Extended Release Oral Tablet tofacitinib 11 MG 24 HR Extended Release Oral Tablet	2	NAMES
TTY	SCD	1	ATTRIBUTES
SPL_SET_ID	13 linked values 11d08738-efa3-4474-8eda-812bc04adfbb 024bb9f2-8c26-4d9d-a33b-eb3c0a7c59ed 141ab3eb-982b-4242-89db-6ddce5be0c40 179ffbb2-bedc-40e6-b77b-33d4f7832172 5502f252-2b39-2cfd-e063-6394a90a8a48 5617a652-a78e-74b1-e063-6394a90a31c7 576722e5-6639-452d-a5c3-33a064f19481 ac0b26d5-1352-42ff-b5ea-3eb02d8508a4 dd62a2b8-300b-d92b-7b27-a30eaa68fdd3 df24e90d-4b2c-4f9d-a1d6-fcb1ab00606f e54b186f-e42a-4477-939c-8dd331045fbe e68680e5-0328-4e66-b8bb-4af126221ec7 f0160e3d-63ea-75fb-4b88-fe3d6a6ce030	13	CODES
RxCUI	1741046	1	CODES
MMSL_CODE	2 linked values BD30704 CD30704	2	CODES

FDA NDC Products And Packages#

Package NDC, Product NDC, Name table
Package NDC	Product NDC	Name	Labeler	Application
0574-1811-30	0574-1811	TOFACITINIB CITRATE Tofacitinib Citrate	Padagis US LLC	ANDA216001
27241-270-30	27241-270	Tofacitinib Tofacitinib	Ajanta Pharma USA Inc.	ANDA219542
42799-970-30	42799-970	Tofacitinib Tofacitinib	Edenbridge Pharmaceuticals LLC.	ANDA218668
50228-567-10	50228-567	TOFACITINIB CITRATE Tofacitinib citrate	ScieGen Pharmaceuticals, INC.	ANDA220972
50228-567-30	50228-567	TOFACITINIB CITRATE Tofacitinib citrate	ScieGen Pharmaceuticals, INC.	ANDA220972
59651-685-30	59651-685	TOFACITINIB TOFACITINIB	Aurobindo Pharma Limited	ANDA218462
60505-4858-3	60505-4858	Tofacitinib tofacitinib	Apotex Corp.	ANDA220458
70377-057-11	70377-057	Tofacitinib Tofacitinib	Biocon Pharma Inc	ANDA219442
70710-1353-3	70710-1353	tofacitinib tofacitinib	Zydus Pharmaceuticals USA Inc.	ANDA214264
70710-1353-9	70710-1353	tofacitinib tofacitinib	Zydus Pharmaceuticals USA Inc.	ANDA214264
70771-1627-3	70771-1627	tofacitinib tofacitinib	Zydus Lifesciences Limited	ANDA214264
70771-1627-9	70771-1627	tofacitinib tofacitinib	Zydus Lifesciences Limited	ANDA214264
73190-102-30	73190-102	Tofacitinib tofacitinib	AvKARE	ANDA220458
76282-816-30	76282-816	TOFACITINIB TOFACITINIB	Exelan pharmaceuticals,Inc	ANDA219830
76333-111-15	76333-111	TOFACITINIB TOFACITINIB	Orient Pharma Co., Ltd. Yunlin Plant	ANDA219830
77771-567-30	77771-567	TOFACITINIB CITRATE Tofacitinib citrate	Radha Pharmaceuticals, Inc.	ANDA220972

Drugs@FDA Applications#

Application, NDC, Name table
Application	NDC	Name	Marketing category	Labeler
ANDA216001	0574-1811	TOFACITINIB CITRATE Tofacitinib Citrate	ANDA	Padagis US LLC
ANDA219542	27241-270	Tofacitinib Tofacitinib	ANDA	Ajanta Pharma USA Inc.
ANDA218668	42799-970	Tofacitinib Tofacitinib	ANDA	Edenbridge Pharmaceuticals LLC.
ANDA220972	50228-567	TOFACITINIB CITRATE Tofacitinib citrate	ANDA	ScieGen Pharmaceuticals, INC.
ANDA218462	59651-685	TOFACITINIB TOFACITINIB	ANDA	Aurobindo Pharma Limited
ANDA220458	60505-4858	Tofacitinib tofacitinib	ANDA	Apotex Corp.
ANDA219442	70377-057	Tofacitinib Tofacitinib	ANDA	Biocon Pharma Inc
ANDA214264	70710-1353	tofacitinib tofacitinib	ANDA	Zydus Pharmaceuticals USA Inc.
ANDA219830	76282-816	TOFACITINIB TOFACITINIB	ANDA	Exelan pharmaceuticals,Inc

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 17 matching rows.

NDC11, Source, Active table
NDC11	Source	Active
00574181130	rxnav_ndcs	yes
27241027030	rxnav_ndcs	yes
42799097030	rxnav_ndcs	yes
50228056710	rxnav_ndcs	yes
50228056730	rxnav_ndcs	yes
59651068530	rxnav_ndcs	yes
60505485803	rxnav_ndcs	yes
70377005711	rxnav_ndcs	yes
70710135303	rxnav_ndcs	yes
70710135309	rxnav_ndcs	yes
70771162703	rxnav_ndcs	yes
70771162709	rxnav_ndcs	yes
73190010230	rxnav_ndcs	yes
76282081630	rxnav_ndcs	yes
76333011115	rxnav_ndcs	yes
77771056730	rxnav_ndcs	yes
84677004830	rxnav_ndcs	yes

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 11 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Tofacitinib	TOFACITINIB	Edenbridge Pharmaceuticals LLC.	576722e5-6639-452d-a5c3-33a064f19481	2026-08-17	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 42799-970-30 ndc (product): 42799-970 ndc11 (package): 42799097030 rxcui: 1741046
tofacitinib	TOFACITINIB	Zydus Pharmaceuticals USA Inc.	179ffbb2-bedc-40e6-b77b-33d4f7832172	2026-08-07	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 70710-1353-3 ndc (package): 70710-1353-9 ndc (product): 70710-1353 ndc11 (package): 70710135303 ndc11 (package): 70710135309 rxcui: 1741046
TOFACITINIB CITRATE	TOFACITINIB CITRATE	Radha Pharmaceuticals, Inc.	141ab3eb-982b-4242-89db-6ddce5be0c40	2026-07-21	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 77771-567-30 ndc (product): 77771-567 ndc11 (package): 77771056730 rxcui: 1741046
TOFACITINIB CITRATE	TOFACITINIB CITRATE	ScieGen Pharmaceuticals, INC.	11d08738-efa3-4474-8eda-812bc04adfbb	2026-07-21	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 50228-567-10 ndc (package): 50228-567-30 ndc (product): 50228-567 ndc11 (package): 50228056710 ndc11 (package): 50228056730 rxcui: 1741046
TOFACITINIB	TOFACITINIB	Aurobindo Pharma Limited	e54b186f-e42a-4477-939c-8dd331045fbe	2026-07-17	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 59651-685-30 ndc (product): 59651-685 ndc11 (package): 59651068530 rxcui: 1741046
TOFACITINIB	TOFACITINIB	Orient Pharma Co., Ltd. Yunlin Plant	5617a652-a78e-74b1-e063-6394a90a31c7	2026-06-30	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 76333-111-15 ndc (product): 76333-111 ndc11 (package): 76333011115 rxcui: 1741046
Tofacitinib	TOFACITINIB	AvKARE	5502f252-2b39-2cfd-e063-6394a90a8a48	2026-06-24	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 73190-102-30 ndc (product): 73190-102 ndc11 (package): 73190010230 rxcui: 1741046
Tofacitinib	TOFACITINIB	Ajanta Pharma USA Inc.	024bb9f2-8c26-4d9d-a33b-eb3c0a7c59ed	2026-06-05	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 27241-270-30 ndc (product): 27241-270 ndc11 (package): 27241027030 rxcui: 1741046
tofacitinib	TOFACITINIB	Zydus Lifesciences Limited	ac0b26d5-1352-42ff-b5ea-3eb02d8508a4	2026-05-12		Exact identifier ndc (package): 70771-1627-9 ndc (package): 70771-1627-3 ndc (product): 70771-1627 ndc11 (package): 70771162703 ndc11 (package): 70771162709 rxcui: 1741046
TOFACITINIB	TOFACITINIB	Exelan pharmaceuticals,Inc	e68680e5-0328-4e66-b8bb-4af126221ec7	2026-05-01	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 76282-816-30 ndc (product): 76282-816 ndc11 (package): 76282081630 rxcui: 1741046
TOFACITINIB CITRATE	TOFACITINIB CITRATE	Padagis US LLC	df24e90d-4b2c-4f9d-a1d6-fcb1ab00606f	2026-04-30	Boxed warning, Warnings, Adverse reactions	Exact identifier ndc (package): 0574-1811-30 ndc (product): 0574-1811 ndc11 (package): 00574181130 rxcui: 1741046

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 5 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
cf74ba2f-afc5-4baa-8594-979c889a5831	tofacitinib 11 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 11 MG Extended Release Oral Tablet [SCD] · tofacitinib 11 MG (as tofacitinib citrate 17.77 MG) 24 HR Extended Release Oral Tablet [SY] · tofacitinib 11 MG 24 HR Extended Release Oral Tablet [SY]	4	53	These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012	20260312
68e3d6b2-7838-4d2d-a417-09d919b43e13	tofacitinib 11 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 11 MG Extended Release Oral Tablet [SCD] · tofacitinib 11 MG (as tofacitinib citrate 17.77 MG) 24 HR Extended Release Oral Tablet [SY] · tofacitinib 11 MG 24 HR Extended Release Oral Tablet [SY]	4	17	These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012	20260327
e54b186f-e42a-4477-939c-8dd331045fbe	tofacitinib 11 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 11 MG Extended Release Oral Tablet [SCD] · tofacitinib 11 MG (as tofacitinib citrate 17.77 MG) 24 HR Extended Release Oral Tablet [SY] · tofacitinib 11 MG 24 HR Extended Release Oral Tablet [SY]	4	7	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	20260312
179ffbb2-bedc-40e6-b77b-33d4f7832172	tofacitinib 11 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 11 MG Extended Release Oral Tablet [SCD] · tofacitinib 11 MG (as tofacitinib citrate 17.77 MG) 24 HR Extended Release Oral Tablet [SY] · tofacitinib 11 MG 24 HR Extended Release Oral Tablet [SY]	4	6	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	20260512
ac0b26d5-1352-42ff-b5ea-3eb02d8508a4	tofacitinib 11 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR tofacitinib 11 MG Extended Release Oral Tablet [SCD] · tofacitinib 11 MG (as tofacitinib citrate 17.77 MG) 24 HR Extended Release Oral Tablet [SY] · tofacitinib 11 MG 24 HR Extended Release Oral Tablet [SY]	4	5	TOFACITINIB Extended-Release Tablets	20260512

Recently Linked DailyMed Labels#

Set ID, Title, Manufacturer table
Set ID	Title	Manufacturer	Effective
dd62a2b8-300b-d92b-7b27-a30eaa68fdd3	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Apotex Corp.	20261008
f0160e3d-63ea-75fb-4b88-fe3d6a6ce030	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Biocon Pharma Inc \| Biocon Pharma Limited	20261007
dd62a2b8-300b-d92b-7b27-a30eaa68fdd3	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Apotex Corp.	20260930
58b94979-55ad-839a-e063-6294a90ad812	TOFACITINIB EXTENDED-RELEASE TABLETS. These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Golden State Medical Supply, Inc.	20260824
576722e5-6639-452d-a5c3-33a064f19481	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Edenbridge Pharmaceuticals LLC.	20260817
58b94979-55ad-839a-e063-6294a90ad812	TOFACITINIB EXTENDED-RELEASE TABLETS. These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Golden State Medical Supply, Inc.	20260810
179ffbb2-bedc-40e6-b77b-33d4f7832172	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Zydus Pharmaceuticals USA Inc. \| Zydus Lifesciences Limited	20260807
dd62a2b8-300b-d92b-7b27-a30eaa68fdd3	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Apotex Corp.	20260727
11d08738-efa3-4474-8eda-812bc04adfbb	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	ScieGen Pharmaceuticals, INC.	20260721
141ab3eb-982b-4242-89db-6ddce5be0c40	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Radha Pharmaceuticals, Inc. \| ScieGen Pharmaceuticals, INC.	20260721
e54b186f-e42a-4477-939c-8dd331045fbe	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Aurobindo Pharma Limited	20260717
5617a652-a78e-74b1-e063-6394a90a31c7	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Orient Pharma Co., Ltd. Yunlin Plant	20260630
5502f252-2b39-2cfd-e063-6394a90a8a48	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	AvKARE	20260624
dd62a2b8-300b-d92b-7b27-a30eaa68fdd3	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Apotex Corp.	20260609
576722e5-6639-452d-a5c3-33a064f19481	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Edenbridge Pharmaceuticals LLC.	20260608
e54b186f-e42a-4477-939c-8dd331045fbe	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Aurobindo Pharma Limited	20260605
024bb9f2-8c26-4d9d-a33b-eb3c0a7c59ed	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Ajanta Pharma USA Inc. \| Ajanta Pharma Limited, Paithan	20260605
576722e5-6639-452d-a5c3-33a064f19481	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Edenbridge Pharmaceuticals LLC.	20260526
dd62a2b8-300b-d92b-7b27-a30eaa68fdd3	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Apotex Corp.	20260522
179ffbb2-bedc-40e6-b77b-33d4f7832172	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Zydus Pharmaceuticals USA Inc. \| Zydus Lifesciences Limited	20260512
ac0b26d5-1352-42ff-b5ea-3eb02d8508a4	TOFACITINIB Extended-Release Tablets	Zydus Lifesciences Limited	20260512
e68680e5-0328-4e66-b8bb-4af126221ec7	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Exelan pharmaceuticals,Inc \| Orient Pharma Co., Ltd. Yunlin Plant	20260501
df24e90d-4b2c-4f9d-a1d6-fcb1ab00606f	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS . TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Padagis US LLC	20260430
f0160e3d-63ea-75fb-4b88-fe3d6a6ce030	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Biocon Pharma Inc \| Biocon Pharma Limited	20260409
e54b186f-e42a-4477-939c-8dd331045fbe	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Aurobindo Pharma Limited	20260312
024bb9f2-8c26-4d9d-a33b-eb3c0a7c59ed	These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012	Ajanta Pharma USA Inc. \| Ajanta Pharma Limited, Paithan	20260125

Drug Classes#

Source, Class ID, Class table
Source	Class ID	Class	Type	Relationship	Drug concept
ATC	L04AF	Janus-associated kinase (JAK) inhibitors	ATC1-4		tofacitinib
FDASPL	N0000190858	Janus Kinase Inhibitor	EPC	has_epc	tofacitinib
FDASPL	N0000190857	Janus Kinase Inhibitors	MOA	has_moa	tofacitinib
MEDRT	D010880	Piperidines	CHEM	has_ingredient	tofacitinib
MEDRT	D011743	Pyrimidines	CHEM	has_ingredient	tofacitinib
MEDRT	D001172	Arthritis, Rheumatoid	DISEASE	may_treat	tofacitinib
MEDRT	N0000190857	Janus Kinase Inhibitors	MOA	has_moa	tofacitinib
MEDRT	N0000008656	Decreased Hematopoiesis	PE	has_pe	tofacitinib
MEDRT	N0000175550	Decreased Immunologic Activity	PE	has_pe	tofacitinib

Group, Type, Concept table
Group	Type	Concept	Source
BN	BN	Xeljanz	rxnav_allrelated
DF	DF	Extended Release Oral Tablet	rxnav_allrelated
DFG	DFG	Oral Product	rxnav_allrelated
DFG	DFG	Pill	rxnav_allrelated
IN	IN	tofacitinib	rxnav_allrelated
SBD	SBD	24 HR tofacitinib 11 MG Extended Release Oral Tablet [Xeljanz]	rxnav_allrelated
SBDC	SBDC	tofacitinib 11 MG [Xeljanz]	rxnav_allrelated
SBDF	SBDF	tofacitinib Extended Release Oral Tablet [Xeljanz]	rxnav_allrelated
SBDG	SBDG	Xeljanz Oral Product	rxnav_allrelated
SBDG	SBDG	Xeljanz Pill	rxnav_allrelated
SCD	SCD	24 HR tofacitinib 11 MG Extended Release Oral Tablet	rxnav_allrelated
SCDC	SCDC	tofacitinib 11 MG	rxnav_allrelated
SCDF	SCDF	tofacitinib Extended Release Oral Tablet	rxnav_allrelated
SCDG	SCDG	tofacitinib Oral Product	rxnav_allrelated
SCDG	SCDG	tofacitinib Pill	rxnav_allrelated

Properties#

Category, Property, Value table
Category	Property	Value
ATTRIBUTES	AVAILABLE_STRENGTH	11 MG
ATTRIBUTES	GENERAL_CARDINALITY	SINGLE
ATTRIBUTES	HUMAN_DRUG	US
ATTRIBUTES	QUANTITY	24 HR
ATTRIBUTES	RXNAV_HUMAN_DRUG	US
ATTRIBUTES	SCHEDULE	0
CODES	ANDA	ANDA214264
CODES	ANDA	ANDA216001
CODES	ANDA	ANDA218462
CODES	ANDA	ANDA218668
CODES	ANDA	ANDA219442
CODES	ANDA	ANDA219542
CODES	ANDA	ANDA219830
CODES	ANDA	ANDA220458
CODES	ANDA	ANDA220972
CODES	SNOMEDCT	1163315009
CODES	VUID	4035481
NAMES	Prescribable Synonym	tofacitinib 11 MG 24HR Extended Release Oral Tablet
SOURCES	Source	Gold Standard Alchemy
SOURCES	Source	Metathesaurus FDA Structured Product Labels
SOURCES	Source	Micromedex RED BOOK
SOURCES	Source	Multum MediSource Lexicon
SOURCES	Source	National Drug Data File Plus Source Vocabulary
SOURCES	Source	US Edition of SNOMED_CT
SOURCES	Source	Veterans Health Administration National Drug File